SG Americas Securities LLC purchased a new stake in shares of Cryolife Inc (NYSE:CRY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 9,998 shares of the medical equipment provider’s stock, valued at approximately $278,000.

Several other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. boosted its holdings in Cryolife by 15.9% in the second quarter. Victory Capital Management Inc. now owns 14,596 shares of the medical equipment provider’s stock worth $406,000 after purchasing an additional 2,002 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Cryolife by 117.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,305 shares of the medical equipment provider’s stock worth $176,000 after purchasing an additional 3,400 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Cryolife by 13.0% in the first quarter. New York State Common Retirement Fund now owns 36,500 shares of the medical equipment provider’s stock worth $732,000 after purchasing an additional 4,200 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Cryolife by 1.9% in the first quarter. Principal Financial Group Inc. now owns 263,759 shares of the medical equipment provider’s stock worth $5,288,000 after purchasing an additional 5,037 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Cryolife by 7.7% in the second quarter. Rhumbline Advisers now owns 81,949 shares of the medical equipment provider’s stock worth $2,282,000 after purchasing an additional 5,858 shares in the last quarter. Institutional investors and hedge funds own 68.92% of the company’s stock.

A number of brokerages recently issued reports on CRY. Northland Securities reiterated a “buy” rating and issued a $32.00 price objective on shares of Cryolife in a report on Tuesday, August 7th. Canaccord Genuity upped their price objective on shares of Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Zacks Investment Research upgraded shares of Cryolife from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Monday, August 13th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $32.75.

Shares of NYSE:CRY opened at $34.60 on Monday. The firm has a market capitalization of $1.27 billion, a P/E ratio of 86.50 and a beta of 0.66. Cryolife Inc has a 1 year low of $16.80 and a 1 year high of $35.05. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.97 and a quick ratio of 3.63.

Cryolife (NYSE:CRY) last issued its quarterly earnings data on Monday, August 6th. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.03. The firm had revenue of $68.50 million during the quarter, compared to analysts’ expectations of $64.08 million. Cryolife had a negative net margin of 2.34% and a positive return on equity of 4.28%. Cryolife’s revenue for the quarter was up 43.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.12 earnings per share. equities analysts anticipate that Cryolife Inc will post 0.31 EPS for the current year.

In other Cryolife news, VP Jean F. Holloway sold 1,500 shares of the business’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $30.50, for a total transaction of $45,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director C Elkins Ronald sold 5,000 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $34.53, for a total transaction of $172,650.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 365,261 shares of company stock valued at $11,828,303. Company insiders own 3.97% of the company’s stock.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Recommended Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.